Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Fresh Tracks Therapeutics, Inc. (VICL)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15Dec-31-14
   10-K10-K10-K10-K10-K10-K10-K10-K
Revenues   [+]0.41.87.910.913.814.521.015.2
            Revenue growth  -77.8%-77.0%-27.3%-21.2%-4.9%-30.6%37.7%97.2%
Cost of goods sold  0.00.00.00.06.56.310.910.8
Gross profit  0.41.87.910.97.38.210.04.4
            Gross margin  100.0%100.0%100.0%100.0%53.1%56.7%47.8%28.9%
Selling, general and administrative   [+]12.411.612.26.46.37.18.49.6
Research and development  28.211.220.213.014.410.411.111.5
EBITDA   [+]-40.2-21.0-24.4-8.4-12.6-8.1-8.2-15.0
            EBITDA margin  -9955.9%-1150.7%-308.7%-77.2%-91.1%-55.5%-39.4%-98.3%
Depreciation  0.00.00.00.00.71.01.01.5
EBITA  -40.2-21.0-24.5-8.5-13.3-9.1-9.2-16.4
            EBITA margin  -9961.4%-1151.3%-309.1%-77.6%-96.1%-62.5%-43.9%-107.9%
Amortization of intangibles      0.10.10.20.2
EBIT   [+]-40.2-21.0-24.5-8.5-13.4-9.2-9.4-16.6
            EBIT margin  -9961.4%-1151.3%-309.1%-77.6%-96.9%-63.2%-44.9%-109.3%
Interest expense, net   [+]-0.8-0.11.91.0    
Other income (expense), net   [+]0.0 2.50.20.40.20.20.1
Pre-tax income  -39.5-20.9-23.9-9.2-13.0-9.0-9.2-16.5
Income taxes  0.00.00.00.00.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income  -39.5-20.9-13.6-15.2-13.0-9.0-9.2-16.5
            Net margin  -9777.2%-1147.8%-171.8%-139.3%-93.8%-61.8%-44.1%-108.4%
   
Basic EPS   [+]($0.49)($0.85)($4.50)($25.85)($1.01)($0.90)($1.01)($1.86)
Diluted EPS   [+]($0.49)($0.85)($4.50)($25.85)($1.01)($0.90)($1.01)($1.86)
   
Shares outstanding (basic)   [+]80.324.53.00.612.910.09.28.9
Shares outstanding (diluted)   [+]80.324.53.00.612.910.09.28.9
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy